These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 17387337)

  • 41. A conditionally replicative adenovirus that codes for a TK-GFP fusion protein (Ad5Delta24TK-GFP) for evaluation of the potency of oncolytic virotherapy combined with molecular chemotherapy.
    Hakkarainen T; Hemminki A; Curiel DT; Wahlfors J
    Int J Mol Med; 2006 Oct; 18(4):751-9. PubMed ID: 16964432
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A fiber-modified, secretory leukoprotease inhibitor promoter-based conditionally replicating adenovirus for treatment of ovarian cancer.
    Rein DT; Breidenbach M; Kirby TO; Han T; Siegal GP; Bauerschmitz GJ; Wang M; Nettelbeck DM; Tsuruta Y; Yamamoto M; Dall P; Hemminki A; Curiel DT
    Clin Cancer Res; 2005 Feb; 11(3):1327-35. PubMed ID: 15709205
    [TBL] [Abstract][Full Text] [Related]  

  • 43. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
    Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
    Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Liposomal enhancement of the antitumor activity of conditionally replication-competent adenoviral plasmids.
    Yotnda P; Davis AR; Hicks MJ; Templeton NS; Brenner MK
    Mol Ther; 2004 Apr; 9(4):489-95. PubMed ID: 15093179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Oncolytic virus therapy for pancreatic cancer using the adenovirus library displaying random peptides on the fiber knob.
    Nishimoto T; Yoshida K; Miura Y; Kobayashi A; Hara H; Ohnami S; Kurisu K; Yoshida T; Aoki K
    Gene Ther; 2009 May; 16(5):669-80. PubMed ID: 19225547
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Benefits of gene transduction of granulocyte macrophage colony-stimulating factor in cancer vaccine using genetically modified dendritic cells.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Nakamori M; Ueda K; Naka T; Katsuda M; Miyazawa M; Yamaue H
    Int J Oncol; 2007 Oct; 31(4):931-9. PubMed ID: 17786327
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
    Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
    Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Adenovirus-mediated granulocyte-macrophage colony-stimulating factor improves lung pathology of pulmonary alveolar proteinosis in granulocyte-macrophage colony-stimulating factor-deficient mice.
    Zsengellér ZK; Reed JA; Bachurski CJ; LeVine AM; Forry-Schaudies S; Hirsch R; Whitsett JA
    Hum Gene Ther; 1998 Sep; 9(14):2101-9. PubMed ID: 9759936
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficient melanoma cell killing and reduced melanoma growth in mice by a selective replicating adenovirus armed with tumor necrosis factor-related apoptosis-inducing ligand.
    Fecker LF; Rückert S; Kurbanov BM; Schmude M; Stockfleth E; Fechner H; Eberle J
    Hum Gene Ther; 2011 Apr; 22(4):405-17. PubMed ID: 20977303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
    Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
    Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.
    Heise CC; Williams AM; Xue S; Propst M; Kirn DH
    Cancer Res; 1999 Jun; 59(11):2623-8. PubMed ID: 10363984
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intratumoral administration of low doses of an adenovirus vector encoding tumor necrosis factor alpha together with naive dendritic cells elicits significant suppression of tumor growth without toxicity.
    Kianmanesh A; Hackett NR; Lee JM; Kikuchi T; Korst RJ; Crystal RG
    Hum Gene Ther; 2001 Nov; 12(17):2035-49. PubMed ID: 11747595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cotargeting tumor and tumor endothelium effectively inhibits the growth of human prostate cancer in adenovirus-mediated antiangiogenesis and oncolysis combination therapy.
    Jin F; Xie Z; Kuo CJ; Chung LW; Hsieh CL
    Cancer Gene Ther; 2005 Mar; 12(3):257-67. PubMed ID: 15565180
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
    Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
    J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.
    Fernández-Ulibarri I; Hammer K; Arndt MA; Kaufmann JK; Dorer D; Engelhardt S; Kontermann RE; Hess J; Allgayer H; Krauss J; Nettelbeck DM
    Int J Cancer; 2015 May; 136(9):2228-40. PubMed ID: 25303768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
    Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
    Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reduced toxicity, attenuated immunogenicity and efficient mediation of human p53 gene expression in vivo by an adenovirus vector with deleted E1-E3 and inactivated E4 by GAL4-TATA promoter replacement.
    Ji L; Bouvet M; Price RE; Roth JA; Fang B
    Gene Ther; 1999 Mar; 6(3):393-402. PubMed ID: 10435089
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination gene therapy using multiple immunomodulatory genes transferred by a defective infectious single-cycle herpes virus in squamous cell cancer.
    Kim SH; Carew JF; Kooby DA; Shields J; Entwisle C; Patel S; Shah JP; Fong Y
    Cancer Gene Ther; 2000 Sep; 7(9):1279-85. PubMed ID: 11023201
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MART1 or gp100 for cancer therapy.
    Zhai Y; Yang JC; Kawakami Y; Spiess P; Wadsworth SC; Cardoza LM; Couture LA; Smith AE; Rosenberg SA
    J Immunol; 1996 Jan; 156(2):700-10. PubMed ID: 8543823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.